13F Data
13F filer · CIK 1812549

RiverVest Venture Management LLC

St. Louis, MO · filing since Q4 2020 · last filing Oct 30, 2024
Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Reported value
$6.8M
+$13.2K vs prior
Positions
3
New / sold out
0 / 1
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $112.3K
Top-10 weight
100.0%

Biggest buys vs Q2 2024

No new or increased positions this quarter.

Biggest sells vs Q2 2024

ChangeSecurityShares changeChange %Est. trade value
Sold outVapotherm, Inc.-52,881-100.0%$-112.3K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2020: $910.3MQ1 2021: $649.3MQ2 2021: $511.6MQ3 2021: $595.6MQ4 2021: $140.2MQ1 2022: $97.4MQ2 2022: $68.0MQ3 2022: $86.1MQ4 2022: $85.7MQ1 2023: $86.4MQ2 2023: $90.2MQ3 2023: $40.4MQ4 2023: $27.1MQ1 2024: $8.1MQ2 2024: $6.8MQ3 2024: $6.8M
Q4 2020Q3 2024

Holdings · Q3 2024

#SecuritySharesValueWeight
1Reneo Pharmaceuticals, Inc.COMMON2,534,220$4.3M63.00%
2Spruce Bioscience, Inc.COMMON2,936,281$1.4M20.39%
3Xilio Therapeutics, Inc.COMMON1,441,444$1.1M16.60%